The BACE2 Knouckout HT29 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout population targeting the BACE2 gene in the HT29 colorectal adenocarcinoma cell line. This heterogeneous cell pool offers a loss-of-function model for investigating BACE2-dependent proteolytic events and signaling pathways without the clonal bias of single-cell-derived lines. The polyclonal format captures diverse editing outcomes, enabling population-based functional studies relevant to Alzheimer??s disease, insulin signaling, and cancer biology.
The HT29 parent line, derived from a 44-year-old female patient with colorectal adenocarcinoma, is a well-established model for intestinal epithelial research and colorectal cancer. HT29 cells retain key epithelial features and express relevant substrates such as APP and insulin receptor, providing a physiologically meaningful context in which to examine BACE2-mediated cleavage activities. Their utility in drug target validation and signaling studies is enhanced by robust adhesion, tumorigenic potential, and compatibility with a wide range of molecular and cellular assays.
BACE2 encodes an aspartic protease that processes substrates including APP, insulin receptor, PMEL, and IL-1R2, while also modulating Notch1 and ACE2 shedding. The enzyme undergoes furin-dependent maturation and interacts with the gamma-secretase complex and adaptor proteins GGA1 and GGA2. BACE2 transcription is regulated by Sp1, NF-??B, and cellular stress, positioning the protease at a hub connecting Alzheimer??s-related APP processing, insulin receptor signaling, and melanosome biogenesis. In the absence of BACE2, cleavage of these targets is impaired, offering a clean background to probe substrate proteolysis and downstream effects.
BACE2 knockout in HT29 cells allows dissection of protease functions specifically in colorectal cancer biology. HT29 cells express insulin receptor and components of the Akt signaling cascade, making them suitable for studying BACE2??s role in insulin receptor shedding and metabolic regulation. Furthermore, the polyclonal knockout population may better mimic heterogeneous tumor responses, facilitating translational studies on receptor shedding, proliferation, and apoptosis relevant to colorectal cancer progression and therapeutic targeting.
Researchers can employ these cells in assays such as Western blotting, RT-qPCR, ELISA for A?? peptides and insulin receptor fragments, immunofluorescence, co-immunoprecipitation, and phospho-signaling analysis of Akt. Functional readouts including proliferation, apoptosis, and migration/invasion assays can be integrated to comprehensively assess BACE2-dependent phenotypes. Key applications span Alzheimer??s disease, type 2 diabetes, Down syndrome, and colorectal cancer research, with particular value in drug target validation and protease substrate identification. For additional details, please contact Ascent Research.
